Dagmar Chase earned a master's degree in Computer Science (secondary focus on Theoretical Medicine) from the Technical University in Munich and holds a doctorate in Human Biology from the Medical Faculty in Ulm, Germany.
Dagmar Chase co-founded, together with Prof. Dr. Albrecht Neiss, the company GMI, a full service CRO for clinical trials phase II - IV, in 1983.
Besides developing GMI into one of the largest CROs in Germany, Dagmar Chase concentrated on Quality Management as well as the development of training programs for the pharmaceutical industry.
After selling GMI to Kendle in 1997, she worked on global development programs, being a vice-president at Kendle. In 2004, Dagmar started up Clinrex, a consultancy firm for clinical research. Besides providing training, she offers services covering all aspects of GCP and Quality Management in clinical trials, e.g., GCP gap analyses, SOP development, audits and inspection readiness programs.
Dagmar Chase is a co-founder of the German CRO association BVMA (Bundesverband Medizinischer Auftragsinstitute e.V.), which was established in 1991. She was the president of the BVMA from 2001 until the end of 2017 and is now an honorary member of the BVMA. Dr. Chase is also a co-founder of EUCROF, the European CRO Federation, and held the position of vice-president for 10 years until the end of 2016. She still chairs the EUCROF Clinical Trials Legislation Working Group and represents EUCROF at numerous EMA stakeholder meetings.
After many years of fruitful cooperation with the BPI (Bundesverband der Pharmazeutischen Industrie e.V.), Dagmar Chase was nominated “BPI Senior Expert” in 2019 in recognition of her knowledge and expertise in clinical research and GCP.